GW Pharmaceuticals PLC- (GWPH) Rating Increased to Buy at BidaskClub

GW Pharmaceuticals PLC- (NASDAQ:GWPH) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

A number of other analysts also recently weighed in on GWPH. Cowen reiterated an “outperform” rating and set a $165.00 price target on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. ValuEngine downgraded GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Leerink Swann reiterated an “outperform” rating and set a $153.00 price target (down from $160.00) on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $208.00 price target on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. Finally, Goldman Sachs Group reissued a “neutral” rating and set a $124.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $148.78.

Shares of GW Pharmaceuticals PLC- (GWPH) opened at $134.61 on Friday. The company has a quick ratio of 7.47, a current ratio of 7.59 and a debt-to-equity ratio of 0.02. GW Pharmaceuticals PLC- has a 1-year low of $92.65 and a 1-year high of $136.95.

Hedge funds have recently added to or reduced their stakes in the company. IHT Wealth Management LLC boosted its position in shares of GW Pharmaceuticals PLC- by 18.0% during the 2nd quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 100 shares in the last quarter. Advisor Group Inc. boosted its position in shares of GW Pharmaceuticals PLC- by 10.7% during the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 145 shares in the last quarter. BNP Paribas Arbitrage SA bought a new position in shares of GW Pharmaceuticals PLC- during the 2nd quarter worth about $163,000. Woodmont Investment Counsel LLC bought a new position in shares of GW Pharmaceuticals PLC- during the 2nd quarter worth about $201,000. Finally, Van Hulzen Asset Management LLC bought a new position in shares of GW Pharmaceuticals PLC- during the 3rd quarter worth about $205,000. 81.79% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “GW Pharmaceuticals PLC- (GWPH) Rating Increased to Buy at BidaskClub” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/22/gw-pharmaceuticals-plc-gwph-rating-increased-to-buy-at-bidaskclub.html.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit